Drugs / ELND002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01318421 | Dec 2010 → Dec 2012 | multiple sclerosis | Elan Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01144351 | Mar 2010 → Dec 2012 | multiple sclerosis | Elan Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELND002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01318421 ↗ |
| Route | Subcutaneous | “Subcutaneous ELND002” NCT01144351 ↗ |